NYXH Nyxoah S.A: Expected earnings per share growth for next year

Nyxoah S.A. develops unique micro-implants to combat apnea, ensuring high margins. However, geopolitical conflicts and sanctions hinder the export of these systems, which is reflected in the shifting consensus estimate for net profit growth: the figure stands at 40.90. The implementation of robotic assembly lines for neurostimulators with AI control should stabilize the trend and enhance the company's production capacities.
Analytical breakdowns for Nyxoah S.A.

Nyxoah S.A. (NYXH) minimizes customs risks by diversifying its production sites across the US and Europe, thereby maintaining high margins for implant deliveries. This indicator captures the consensus earnings per share (EPS) growth forecast, measuring the weighted average expectations of analysts regarding future earnings. The current value of 40.90 allows for a fundamental revaluation of the business, stripped of market noise. The positive trend in the consensus EPS forecast signals a strengthening of the company's investment potential.